KAYTUS
14.5.2024 09:01:36 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, has unveiled MotusAI, an AI development platform now accessible for trial worldwide. MotusAI is tailored for deep learning and AI development, integrating GPU and data resources alongside AI development environments to streamline computing resource allocation, task orchestration, and centralized management. It accelerates training data and manages AI model development workflows seamlessly. This platform drastically reduces resource investment, boosts development efficiency, elevates cluster computing power utilization to over 70%, and significantly enhance in large-scale training task scheduling performance.
Streamline AI Development for Cost-Effectiveness and Efficiency
The rapid expansion of enterprise AI business and AI model development brings forth challenges including low computing efficiency, complexity in model development, varied requirements for task orchestration across different scenarios, and unstable computing resources. Ensuring efficient, flexible, and stable operation of AI business is critical for enterprises to consistently derive business insights, generate revenue, and maintain competitiveness.
Optimize Resource Management for Maximum Computing Power
MotusAI efficiently allocates resources and workloads by implementing intelligent and flexible GPU scheduling. It caters to diverse AI workload demands for computing power by dynamically allocating GPU resources based on demand. With multi-dimensional and dynamic GPU resource allocation, including fine-grained GPU scheduling and support for Multi-Instance GPU (MIG), MotusAI effectively meets computing power requirements across various scenarios such as model development, debugging, and training.
Streamline Task Orchestration for Versatile Support of Various Scenario
MotusAI has revolutionized cloud-native scheduling systems. Its scheduler surpasses the community version by dramatically improving the scheduling performance of large-scale POD tasks. MotusAI achieves rapid startup and environment readiness for hundreds of PODs, boasting a five times increase in throughput and a five times decrease in latency compared to the community scheduler. This ensures efficient scheduling and utilization of computing resources for large-scale training. Moreover, MotusAI enables dynamic scaling of AI workloads for both training and inference services, supporting burst tasks and fulfilling diverse scheduling needs across various scenarios.
MotusAI empowers users to maximize computing resources, spanning from fine-grained division of single-card multiple instances to large-scale parallel computing across multiple machines and cards. By integrating features like computing power pooling, dynamic scaling, and GPU single-card reuse, MotusAI significantly enhances computing power utilization, achieving an average utilization rate of over 70%. Furthermore, it enhances computing efficiency by leveraging cluster topology awareness and optimizing network communication.
Data Transfer Acceleration for Three Times Efficiency Improvement
MotusAI excels in data transfer acceleration through innovative features such as supporting local loading and computing of remote data, which eliminates delays caused by network I/O during computation. Utilizing strategies like "zero-copy" data transfer, multi-threaded retrieval, incremental data updates, and affinity scheduling, MotusAI significantly reduces data caching cycles. These enhancements greatly improve AI development and training efficiency, resulting in 2-3 times boost in model efficiency during data training.
Reliable, and Automatically Fault-Tolerant Platform
MotusAI supports performance monitoring and alerts for computing resources, providing real-time status updates for core platform services. It employs sandbox isolation mechanisms for data with higher security levels. In case of resource failures or abnormalities, MotusAI automatically initiates fault tolerance processes to ensure the quickest possible recovery during interrupted training tasks. This approach reduces fault handling time by over 90%, on average.
Comprehensive Management of AI Model Development in One Integrated Solution
MotusAI accelerates AI development and supports every stage of large model development. From managing data samples and software stacks to designing model architectures, debugging code, training models, tuning parameters, and conducting evaluation testing, MotusAI offers a complete platform. It integrates popular development frameworks like PyTorch and TensorFlow, along with distributed training frameworks such as Megatron and DeepSpeed.
Moreover, MotusAI enables comprehensive lifecycle management of AI inferencing services, including offline and online testing, A/B testing, rolling release, service orchestration, and service decommissioning. These features collectively enhance the business value of AI technology, fostering continuous business growth.
Additionally, MotusAI provides an integrated visual management and operation interface that covers computing, networking, storage, and application resources. Operational staff can comprehensively manage, monitor, and evaluate the overall platform operation status through a single interface.
Free Trial Available
MotusAI is now available worldwide for a trial period, offering free remote access for one month, along with testing, training, and support. Users can also opt for local deployment using their own devices and environment, with local deployment testing support from KAYTUS. For more information1 and to register2, please visit Link1, Link2.
About KAYTUS
KAYTUS is a premier provider of IT infrastructure products and solutions, delivering a suite of cutting-edge, open, and environmentally friendly infrastructure solutions for cloud, AI, edge computing, and other emerging technologies. With a customer-centric approach, KAYTUS adapts flexibly to user needs through its agile business model. Learn more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513665403/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
